Equities

Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)5.75
  • Today's Change-0.19 / -3.20%
  • Shares traded568.55k
  • 1 Year change-31.87%
  • Beta0.8778
Data delayed at least 15 minutes, as of Apr 26 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

  • Revenue in SEK (TTM)57.50m
  • Net income in SEK-326.80m
  • Incorporated2006
  • Employees27.00
  • Location
    Egetis Therapeutics AB (publ)Klara Norra Kyrkogata 26STOCKHOLM 111 22SwedenSWE
  • Phone+46 86797210
  • Fax+46 86635725
  • Websitehttps://www.egetis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
XSpray Pharma AB (publ)0.00-179.67m1.01bn26.00--1.82-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Vistin Pharma ASA433.66m45.16m1.05bn79.0023.223.2816.822.421.031.039.887.281.092.167.75--11.331.7314.642.1159.7059.0110.412.361.306.81----52.3717.111,067.85---0.2357--
Cereno Scientific AB0.00-48.11m1.13bn5.00--4.36-----0.241-0.2410.000.92580.00----0.00-19.22-16.81-20.75-18.26-----------12.920.1734-------73.95--44.79--
Infant Bacterial Therapeutics AB0.00-123.07m1.14bn8.00--3.88-----9.90-9.900.0022.650.00----0.00-35.11-16.11-38.65-16.69------------0.00-------88.03------
SyntheticMR AB (publ)89.21m10.01m1.19bn37.00116.5610.1873.0913.320.24450.24452.172.800.6599--1.612,411,162.007.417.198.898.85105.78106.7411.229.08--14.130.010721.5030.6713.0570.34-7.3326.79--
Diamyd Medical AB282.00k-120.18m1.21bn26.00--6.23--4,280.08-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
Arcticzymes Technologies ASA117.67m18.52m1.31bn61.0070.244.2952.6811.120.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Hansa Biopharma AB165.88m-844.88m1.44bn166.00------8.67-16.07-16.073.15-7.100.142464.031.86987,386.90-72.51-47.96-92.27-56.1256.8064.18-509.33-835.042.55-9.651.65---13.22109.06-36.09---35.24--
Photocure ASA495.32m264.15k1.49bn106.007,715.883.1153.743.000.00720.007218.5817.790.70010.82039.37--0.0375-3.090.0429-3.5694.7893.640.0535-5.194.32--0.00--27.3522.50100.37--49.83--
BioInvent International AB71.46m-330.30m1.65bn111.00--1.26--23.16-5.02-5.021.0919.900.0459--5.16643,792.80-21.23-17.50-22.40-18.64-----462.22-131.6314.77--0.0174---78.0913.14-677.13--28.17--
Egetis Therapeutics AB (publ)57.50m-326.80m1.68bn27.00--3.08--29.26-1.28-1.280.2241.860.08716.923.592,129,630.00-49.44-33.02-55.92-36.4680.87---568.00-357.723.32--0.1688--154.8715.35-68.68------
Devyser Diagnostics AB169.30m-53.60m1.71bn118.00--4.44--10.10-3.31-3.3110.4623.650.3351.595.531,434,746.00-10.65-8.97-12.00-10.1585.5380.14-31.78-23.915.11--0.1626--33.7128.59-16.64--44.59--
Genovis AB158.23m61.50m1.87bn37.0030.349.7826.2011.790.93940.93942.422.910.7203----4,276,514.0027.9918.5630.7421.4572.2065.5138.8723.88--------54.5435.56449.56------
Vicore Pharma Holding AB0.00-310.94m1.93bn24.00--4.24-----3.24-3.240.004.080.00----0.00-74.40-58.65-83.09-65.58------------0.00-------7.81------
Nanoform Finland Oyj29.97m-242.46m1.97bn165.00--2.52--65.89-0.2674-0.26740.03310.85350.0287138.934.1115,548.42-23.22-27.13-25.12-29.48-507.09-604.26-809.08-1,023.708.16--0.0964---26.4161.315.98--53.92--
Probi AB607.54m-602.00k2.38bn167.00--1.6724.823.92-0.0528-0.052853.32125.160.38853.236.523,797,144.00-0.03854.64-0.04074.9832.3942.04-0.09919.836.22--0.035321.421.520.7684-58.60-26.0931.01--
Data as of Apr 26 2024. Currency figures normalised to Egetis Therapeutics AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

14.92%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 202321.40m7.32%
Handelsbanken Fonder ABas of 12 Jun 202313.55m4.63%
Unionen (Investment Management)as of 28 Jun 20234.94m1.69%
SEB Investment Management ABas of 28 Mar 20241.44m0.49%
FCG Fonder ABas of 30 Jun 20221.19m0.41%
Financi�re Arbevel SAas of 30 Dec 2022500.00k0.17%
E. �hman J :or Fonder ABas of 29 Feb 2024426.93k0.15%
Skandia Investment Management ABas of 29 Feb 2024152.14k0.05%
Dimensional Fund Advisors LPas of 04 Apr 202450.02k0.02%
More ▼
Data from 31 Oct 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.